Stay updated on Pembrolizumab for Refractory Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase II clinical trial for Pembrolizumab in advanced esophageal cancer, while adding references to collaborators and a new version revision.SummaryDifference49%
- Check44 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check88 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check102 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab for Refractory Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.